Completed PHASE1 INTERVENTIONAL 6-arm NCT00845000

Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients

Sponsor: Merck Sharp & Dohme LLC

Interventions Carbidopa Levodopa Placebo SCH 420814 10 mg SCH 420814 100 mg

Updated 10 times since 2017 Last updated: Oct 9, 2018 Started: Apr 21, 2009 Primary completion: Apr 30, 2010 Completion: May 14, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00845000, this PHASE1 trial focuses on Parkinson Disease and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 10 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jun 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Dec 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Oregon Health and Science University

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.